|
| Status |
Public on Oct 02, 2012 |
| Title |
Expression data from prostate cancer Docetaxel-resistant cells |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Docetaxel is the standard first line therapy for hormone-refractory prostate cancer patients. Here we generated models of Docetaxel resistance in prostate cancer cells to study the molecular pathways that drive the acquisition of resistance to this therapy. We used microarrays to detail the global program of gene expression underlying the acquisition of Docetaxel resistance in prostate cancer cells.
|
| |
|
| Overall design |
Parental Docetaxel-sensitive prostate cancer cell lines (DU145 and 22Rv1) and selected Docetaxel-resistant cells (DU145-DR and 22Rv1-DR) were harvested for RNA extraction and hybridization on Affymetrix microarrays. Samples were analyzed in triplicates in order to increase the resolution of expression profiles.
|
| |
|
| Contributor(s) |
Domingo-Domenech J, Cordon-Cardo C |
| Citation(s) |
22975379 |
| Submission date |
Feb 28, 2012 |
| Last update date |
Mar 25, 2019 |
| Contact name |
Josep Domingo-Domenech |
| E-mail(s) |
josep.domingo-domenech@mssm.edu
|
| Phone |
212-241-9145
|
| Organization name |
Mount Sinai School of Medicine
|
| Department |
Pathology
|
| Street address |
Annenberg Building, Room 24-16
|
| City |
New York |
| State/province |
New York |
| ZIP/Postal code |
10029 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
| GPL571 |
[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array |
|
| Samples (12)
|
|
| Relations |
| BioProject |
PRJNA152947 |
Less...
More...